Showing results (271-280 of 618) with videos related to

Sort By:
Pageof 62
Neuro-Oncology|October 23, 2023
Systematic characterization of antibody-drug conjugate targets in central nervous system tumorsShannon Coy, Jong Suk Lee, Sabrina J Chan, et al.
Neuro-Oncology|June 30, 2016
Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomasBiqi Zhang, Ken Chang, Shakti Ramkissoon, et al.
AJR. American Journal of Roentgenology|October 18, 2018
Voxel-Wise Analysis of Fluoroethyltyrosine PET and MRI in the Assessment of Recurrent Glioblastoma During Antiangiogenic TherapyElizabeth George, Marie F Kijewski, Shipra Dubey, et al.
Neuro-Oncology|October 11, 2025
Characterization of Focal Leptomeningeal Extension in Patients with Brain Metastases: A Novel EntityNayan Lamba, Lianne Kraemer, Rifaquat Rahman, et al.
Neuro-Oncology|March 9, 2018
The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?Alyssa M Vanderbeek, Rifaquat Rahman, Geoffrey Fell, et al.
Neuro-Oncology|February 14, 2018
Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomasMin Zhou, Yue Zhou, Huijun Liao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 27, 2014
Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLCHideho Okada, Lisa H Butterfield, Ronald L Hamilton, et al.
Neuro-Oncology|June 8, 2022
Investigational PET tracers in neuro-oncology-What's on the horizon? A report of the PET/RANO groupNorbert Galldiks, Karl-Josef Langen, Nathalie L Albert, et al.
Neuro-Oncology|November 11, 2022
Incidence proportion and prognosis of leptomeningeal disease among patients with breast vs. non-breast primariesNayan Lamba, Daniel N Cagney, Paul J Catalano, et al.
Journal of Neuro-Oncology|July 9, 2011
Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment deliveryMark R Gilbert, John Kuhn, Kathleen R Lamborn, et al.
Pageof 62